KRAS G12D Inhibitor-induced Resistant Tumor Models
KRAS mutations act as primary initiators of carcinogenesis in several major cancers and are present in approximately 20 – 25% of all human tumors. KRAS G12D is the most frequent KRAS mutation in both colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC), driving tumor progression and acting as a key therapeutic target.
While KRAS G12D-selective inhibitors have shown promising antitumor activity in clinical trials, the development of acquired resistance is recognized as a challenge to long-term therapeutic effectiveness. To support research on developing targeted and combination therapies to overcome this resistance, WuXi Biology has established several KRAS G12D inhibitor–induced resistant tumor models.
KRAS G12D Inhibitor-induced Resistant Tumor Models
Related Content
Many oncology drug candidates with promising preclinical activity ultimately fail because safety liabilities emerge too late in development. An integrated...
VIEW RESOURCEBispecific antibodies have emerged as an important modality in oncology, although their broader application can be limited by manufacturing complexity...
VIEW RESOURCE